Immunomedics (IMMU) Resubmits BLA to FDA for Sacituzumab Govitecan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Wall Street climbs as Broadcom and other chipmakers rally
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Dara Khosrowshahi steps down from Grab Holdings board
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Wall Street climbs as Broadcom and other chipmakers rally
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
December 3, 2019 8:00 AM ESTMORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with... More
